MedTrace Logo

Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)

NCT05885009 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2025-08-06

No results posted yet for this study

Summary

HOPE Prostate is an observational study that aims at promoting research against metastatic prostate cancer by means of collective research led by patients (patient-centric trial). Patients with metastatic prostate cancer living in Spain will voluntarily register and fulfil their journey in the study through the study's digital tool. Mainly they are prompted to answer questionnaires about their disease, and to provide a blood sample and an archival tumor biopsy. In HOPE Prostate these samples will be genomically analyzed and every patient case will be presented in a multidisciplinary molecular advisory board (MAB). The MAB will issue a plain report explaining the significance of the results and will try to enumerate future therapeutic options that match patient history and his genomic profile. Finally, patients will have to answer short follow-up questionnaires twice a year for 3 years.

The study data will allow us to advance implementing precision medicine to improve the management of current and specially future metastatic prostate cancer patients.

Conditions

Interventions

GENETIC

Liquid Biopsy

Patients with metastatic prostate cancer in disease progression or not receiving active systemic therapy will undergo a liquid biopsy

GENETIC

Archival Tumor DNA sequencing

Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • AstraZeneca

    collaborator INDUSTRY

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Advanced Accelerator Applications

    collaborator INDUSTRY

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • Guardant Health, Inc.

    collaborator INDUSTRY

  • SOLTI Breast Cancer Research Group

    lead OTHER

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-28
Primary Completion
2026-03-28
Completion
2028-03-28

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05885009 on ClinicalTrials.gov